Eli Lilly And Company ((LLY)) announced an update on their ongoing clinical study.
Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Study Overview: Eli Lilly and Company is conducting a Phase 3 study titled ‘ACHIEVE-2’ to evaluate the efficacy and safety of orforglipron compared to dapagliflozin in adults with type 2 diabetes who have inadequate glycemic control with metformin. This study is significant as it aims to improve blood sugar management, a critical aspect of diabetes care.
Intervention/Treatment: The study tests two oral drugs: orforglipron, an experimental treatment, and dapagliflozin, an active comparator. Both are designed to enhance blood sugar control in patients with type 2 diabetes.
Study Design: This interventional study uses a randomized, parallel assignment model without masking, focusing primarily on treatment effectiveness. Participants are allocated to receive either orforglipron or dapagliflozin.
Study Timeline: The study began on January 10, 2024, with a primary completion date estimated around 46 weeks later. The latest update was submitted on July 1, 2025, indicating ongoing progress.
Market Implications: This study could impact Eli Lilly’s stock performance positively if orforglipron demonstrates superior efficacy. Investors should watch for results that may influence market dynamics, especially in the competitive diabetes treatment sector.
The study is ongoing, with further details available on the ClinicalTrials portal.